Earth Science Tech Inc. (OTC: ETST) continues to strengthen its operational and financial frameworks, positioning itself as an outlier among over-the-counter stocks. The strategic holding company, operating in healthcare, pharmacy, and telemedicine, has reported year-over-year revenue growth since fiscal 2024, driven by careful acquisitions that have not added debt to its balance sheet. According to Investopedia, a primary risk of OTC stocks is the lack of reliable information, making it difficult for investors to evaluate their potential (https://ibn.fm/4qcql). However, Earth Science Tech overcomes this stigma through timely filings, robust corporate structure, vertical integration, and ownership of hard real estate assets.
The company’s fiscal year 2026 annual report, ended March 31, 2026, shows revenue of $35.7 million, up from $33.1 million in FY2025 (https://ibn.fm/gmnx1) and $11.95 million in FY2024 (https://ibn.fm/cUtl7). Gross profit also rose to $25.5 million in FY2026. These results reflect the company’s strategy of complementary investments and acquisitions, such as the purchase of Avenvi, which created a subsidiary that develops, manages, and finances real estate. This subsidiary owns property housing ETST’s Texas pharmacy, adding tangible assets to the company’s portfolio.
Earth Science Tech’s vertical integration and real estate holdings provide a level of transparency and stability uncommon in the OTC market. Investors can access the company’s newsroom for updates (https://ibn.fm/ETST). This approach not only mitigates the risks associated with penny stocks but also demonstrates a sustainable growth model. By maintaining a debt-free balance sheet and focusing on operational efficiency, ETST aims to continue its trajectory of financial improvement, offering a clearer picture to investors seeking opportunities beyond traditional exchanges.
